Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus TERAZOL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus TERAZOL 3.
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER vs TERAZOL 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole selectively inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Terconazole is an azole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death.
200-400 mg IV once daily; for candidemia or invasive candidiasis, loading dose of 800 mg IV on day 1, then 400 mg IV once daily.
One applicatorful (approximately 5 g of 0.8% terconazole vaginal cream) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life approximately 30 hours (range 20-50 hours). Prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min).
The terminal elimination half-life after intravaginal application is approximately 4-6 hours, reflecting local retention and slow systemic absorption of the small absorbed fraction.
Renal: 80% unchanged drug; feces: 11%; biliary: minor.
Following intravaginal administration, terconazole is minimally absorbed (<5%) into systemic circulation. Absorbed drug is primarily metabolized in the liver and excreted via feces (approximately 50-60% as metabolites) and urine (approximately 20-30% as metabolites). Unabsorbed drug is excreted in feces.
Category A/B
Category C
Azole Antifungal
Azole Antifungal